NovaBay Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in developing and commercializing innovative therapies. The company is dedicated to providing advanced solutions in areas such as the treatment of infections and inflammation. NovaBay Pharmaceuticals Inc holds a strong commitment to improving patients' quality of life through their cutting-edge products and technologies. Their corporate philosophy revolves around fostering a culture of innovation, maintaining the highest standards of integrity, and delivering exceptional value to both patients and shareholders. As a result, NovaBay Pharmaceuticals Inc continues to make significant strides in the pharmaceutical industry by providing effective, reliable, and safe treatment options for a wide range of medical conditions.

NovaBay Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of non-antibiotic, anti-infective products. With its headquarters based in Emeryville, California, NovaBay Pharmaceuticals Inc has a strong presence and market recognition in the American biopharmaceutical industry. The company is dedicated to improving the lives of patients by addressing unmet medical needs, particularly in dermatology, ophthalmology, and wound care. NovaBay Pharmaceuticals Inc's innovative products and therapies have gained recognition from healthcare professionals and consumers alike, making it a prominent player in the United States.

NovaBay Pharmaceuticals Inc, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully developed a proprietary, FDA-cleared technology called Neutrox, which is used in various antimicrobial applications. Secondly, NovaBay Pharmaceuticals Inc obtained regulatory approvals for several of its products, including Avenova, a prescription eyelid and eyelash cleanser. Moreover, the company has successfully expanded its global presence by establishing partnerships and distribution agreements in different regions. Additionally, NovaBay Pharmaceuticals Inc has been consistently conducting clinical trials to explore the potential applications of its products in various medical fields. These achievements demonstrate the company's dedication to innovation and improving patient care.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing non-antibiotic, antimicrobial products. Founded in 2000, NovaBay has been dedicated to providing innovative solutions for infectious diseases, particularly those caused by drug-resistant bacteria. With a focus on developing proprietary compounds based on its Aganocide® technology platform, the company aims to address unmet medical needs in various healthcare settings. NovaBay Pharmaceuticals has gained recognition for its research and development efforts aimed at treating conditions such as urinary catheter blockage and impetigo. The company has established a strong presence in the healthcare industry, leveraging its expertise to develop effective and safe antimicrobial products.

The main competitors of NovaBay Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc., and Abbott Laboratories.

NovaBay Pharmaceuticals Inc is primarily active in the healthcare and pharmaceutical industries.

The business model of NovaBay Pharmaceuticals Inc is focused on developing and commercializing non-antibiotic anti-infective products for the healthcare industry. The company primarily operates in two segments: Avenova® for the domestic eye care market and CelleRx® for the global dermatology market. NovaBay's patented products aim to address unmet medical needs by providing innovative and effective solutions for treating infections without promoting antibiotic resistance. With a strategic focus on the ophthalmology and dermatology markets, NovaBay Pharmaceuticals Inc aims to enhance patient care and generate sustainable growth through its advanced non-antibiotic anti-infective products.

Poměr NovaBay Pharmaceuticals P/E je -0,00.

Koeficient NovaBay Pharmaceuticals tržních hodnot je 0,01.

AlleAktien kvalitní skóre pro NovaBay Pharmaceuticals je 4/10.

očekávané NovaBay Pharmaceuticals obrat je 10,90 mil. USD.

očekávané NovaBay Pharmaceuticals zisk je -16,84 mil. USD.

NovaBay Pharmaceuticals Inc is a biotechnology company that focuses on the development of antibiotics for the treatment of infectious diseases. The company has made a name for itself in various areas and is known for its innovative products. One important area of NovaBay Pharmaceuticals is ophthalmology. The company has developed the products Avenova and CelleRx, which are used for the treatment of eye infections. Avenova is a product for eye cleansing based on the basic-neutral hypochlorous acid formula. It helps reduce bacteria and has antiseptic properties. CelleRx is a solution used to combat infections of eye diseases and can help with the treatment of blepharitis and conjunctivitis. Another important area of NovaBay Pharmaceuticals is dermatology. Here, the company has launched the product NeutroPhase. This product is suitable for the treatment of skin infections and wounds. NeutroPhase contains the same basic-neutral hypochlorous acid formula as Avenova and has antiseptic and antibacterial properties. NovaBay Pharmaceuticals also deals with infectious diseases in animals and has developed the product Vetericyn. This solution is used for wound cleansing and the treatment of infections in pets. The business model of NovaBay Pharmaceuticals is based on the development of new, innovative products for the treatment of infectious diseases. In order to market its products, it works closely with doctors, pharmacists, and distribution partners. The company holds several patents and strives to sell its products worldwide. An important part of NovaBay Pharmaceuticals' business model is also collaborating with other companies in the healthcare sector. For example, the company has partnered with BioClin Therapeutics to jointly develop a new medication for the treatment of skin cancer. Conclusion: NovaBay Pharmaceuticals is a biotechnology company specializing in the development of new, innovative products for the treatment of infectious diseases. The company has made a name for itself in various areas and offers solutions for the treatment of eye, skin, and animal infections. The business model is based on close collaboration with other companies in the healthcare sector and the global sale of its products.

NovaBay Pharmaceuticals vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro NovaBay Pharmaceuticals momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti NovaBay Pharmaceuticals je US66987P2011.

WKN společnosti NovaBay Pharmaceuticals je A2ACBF.

Ticker společnosti NovaBay Pharmaceuticals je NBY.

Během posledních 12 měsíců vyplatila společnost NovaBay Pharmaceuticals dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že NovaBay Pharmaceuticals vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti NovaBay Pharmaceuticals aktuálně činí .

NovaBay Pharmaceuticals vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

NovaBay Pharmaceuticals vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

NovaBay Pharmaceuticals je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě NovaBay Pharmaceuticals ve výši 0 USD, zaznamenané 26. 9. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 26. 9. 2024.

Poslední dividendy byly vyplaceny dne 26. 9. 2024.

V roce 2023 společností NovaBay Pharmaceuticals bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti NovaBay Pharmaceuticals jsou vypláceny v USD.